Back

PD-L1 mediated T cell inhibition by regulatory plasma cells induced after sepsis and COVID-19

Gossez, M.; Vigneron, C.; Vandermoeten, A.; Lepage, M.; Courcol, L.; Coudereau, R.; Paidassi, H.; Jallades, L.; Lopez, J.; Kandara, K.; Ortillon, M.; Mommert, M.; Fabri, A.; Peronnet, E.; Grosjean, C.; Buisson, M.; Lukaszewicz, A.-C.; Rimmele, T.; Argaud, L.; Cour, M.; Py, B. F.; Thaunat, O.; Defrance, T.; monneret, g.; VENET, F.

2024-08-08 intensive care and critical care medicine
10.1101/2024.08.08.24311630 medRxiv
Show abstract

A better understanding of sepsis-induced immunosuppression pathophysiology is desirable for the development of novel therapeutic strategies to prevent and reduce the rates of secondary infections and their associated mortality. Here we demonstrate that PD-L1+CD44+B220LowCD138+IgM+ regulatory plasma cells (PCs) are induced in a murine model of sepsis-induced immune alterations and in critically ill patients with bacterial sepsis and COVID-19. This was revealed both by detailed analysis of their phenotypical features and gene expression profile and by functional explorations comparing capacity of purified B cells and PCs to suppress T cell proliferation and IFN{gamma} secretion ex vivo. Sepsis-induced regulatory PCs exerted their suppressive function on T cells through IL-10 production and increased PD-L1 expression independently of regulatory T cells. Our findings thus reveal a novel pathophysiological mechanism of sepsis-induced immunosuppression that involves regulatory PCs. As such, these PCs constitute valid therapeutic targets to improve immune cell functions impaired by sepsis.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.